Abstract
Protein misfolding has been implicated in the pathophysiology of several neurodegenerative ‘amyloidoses’ that includes Alzheimers, Parkinsons, Huntingtons disease, frontotemporal dementia and amyotrophic lateral sclerosis. Accumulation of misfolded proteins into ordered fibrillar intra- or extracellular amyloids results in brain lesions that in turn lead to injury and neuronal loss. The appearance of protein aggregates in the diseased brain hints at an inability of cellular chaperones to properly assist folding of client proteins. Not surprisingly, studies involving cell-based and animal models of the neurodegenerative diseases have shown that overexpression of molecular chaperones can provide neuroprotection. Together with identification of new targets for symptomatic relief of motor and non-motor defects in neurodegenerative disorders, there is a critical unmet clinical need for the development of novel neuroprotective molecules. One such promising class of compounds are neuroimmunophilin ligands (NILs). Derived from FK506 (tacrolimus), NILs have been shown to be efficacious in a number of neurodegenerative disorders. The ability of these nonimmunosuppressive NILs to protect neurons is modulated, in part, by a large family of co-chaperone proteins called the FK506 binding proteins (FKBPs). This review focuses on the roles of FKBPs in neurodegenerative disorders with an emphasis on the cellular mechanisms responsible for their neuroprotective and neurotrophic activities. We discuss the structural features of FKBPs and the mode of action of NILs. For brevity, we limit our discussion to those FKBPs that are particularly enriched in the nervous system. We hope that such information will aid in the rational design of new and improved NILs for ameliorating neurodegenerative disorders.
Keywords: FK506 binding proteins FKBPs), neurodegenerative disorders, FK506 (Tacrolimus), PPIase activity, neuroimmunophilin ligand, pathophysiology, amyloidoses, frontotemporal dementia, amyotrophic lateral sclerosis, misfolded proteins, neuroimmunophilin ligand (NIL)
Current Medicinal Chemistry
Title: Role of FK506 Binding Proteins in Neurodegenerative Disorders
Volume: 18 Issue: 35
Author(s): S. Chattopadhaya, A. Harikishore and H. S. Yoon
Affiliation:
Keywords: FK506 binding proteins FKBPs), neurodegenerative disorders, FK506 (Tacrolimus), PPIase activity, neuroimmunophilin ligand, pathophysiology, amyloidoses, frontotemporal dementia, amyotrophic lateral sclerosis, misfolded proteins, neuroimmunophilin ligand (NIL)
Abstract: Protein misfolding has been implicated in the pathophysiology of several neurodegenerative ‘amyloidoses’ that includes Alzheimers, Parkinsons, Huntingtons disease, frontotemporal dementia and amyotrophic lateral sclerosis. Accumulation of misfolded proteins into ordered fibrillar intra- or extracellular amyloids results in brain lesions that in turn lead to injury and neuronal loss. The appearance of protein aggregates in the diseased brain hints at an inability of cellular chaperones to properly assist folding of client proteins. Not surprisingly, studies involving cell-based and animal models of the neurodegenerative diseases have shown that overexpression of molecular chaperones can provide neuroprotection. Together with identification of new targets for symptomatic relief of motor and non-motor defects in neurodegenerative disorders, there is a critical unmet clinical need for the development of novel neuroprotective molecules. One such promising class of compounds are neuroimmunophilin ligands (NILs). Derived from FK506 (tacrolimus), NILs have been shown to be efficacious in a number of neurodegenerative disorders. The ability of these nonimmunosuppressive NILs to protect neurons is modulated, in part, by a large family of co-chaperone proteins called the FK506 binding proteins (FKBPs). This review focuses on the roles of FKBPs in neurodegenerative disorders with an emphasis on the cellular mechanisms responsible for their neuroprotective and neurotrophic activities. We discuss the structural features of FKBPs and the mode of action of NILs. For brevity, we limit our discussion to those FKBPs that are particularly enriched in the nervous system. We hope that such information will aid in the rational design of new and improved NILs for ameliorating neurodegenerative disorders.
Export Options
About this article
Cite this article as:
Chattopadhaya S., Harikishore A. and S. Yoon H., Role of FK506 Binding Proteins in Neurodegenerative Disorders, Current Medicinal Chemistry 2011; 18 (35) . https://dx.doi.org/10.2174/092986711798194441
DOI https://dx.doi.org/10.2174/092986711798194441 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Antidepressant Administration Modulates Neural Stem Cell Survival and Serotoninergic Differentiation Through Bcl-2
Current Neurovascular Research Recent Highlights on Molecular Hybrids Potentially Useful in Central Nervous System Disorders
Mini-Reviews in Medicinal Chemistry Transforming Cytosolic Proteins into “Insoluble” and Membrane-toxic Forms Triggering Diseases/Aging by Genetic, Pathological or Environmental Factors
Protein & Peptide Letters Interaction of Dehydrogenase Enzymes with Nanoparticles in Industrial and Medical Applications, and the Associated Challenges: A Mini-review
Mini-Reviews in Medicinal Chemistry Neuropsychiatric Disturbances in Alzheimer’s Disease: What Have We Learned from Neuropathological Studies?
Current Alzheimer Research Pharmacophore-based Drug Design of Novel Potential Tau Ligands for Alzheimer's Disease Treatment
Current Physical Chemistry Special Issue on Stem Cells: An Introduction from the Guest Editor
Current Neurovascular Research Stem Cells with Neurogenic Potential and Steroid Hormones
Current Topics in Medicinal Chemistry Frontier View on Nanotechnological Strategies for Neuro-therapy
Current Drug Metabolism Protein Chemistry of Amyloid Fibrils and Chaperones: Implications for Amyloid Formation and Disease
Current Chemical Biology New Strategies for the Synthesis of Bio-medically Relevant Oligosaccharides: Recent Updates on 1,2-cis-O-Glycosylation and α-O-Sialylation
Current Organic Synthesis Large-Conductance Ca2+-Activated K+ Channels:Physiological Role and Pharmacology
Current Medicinal Chemistry Understanding the Role of Hypoxia Inducible Factor During Neurodegeneration for New Therapeutics Opportunities
Current Neuropharmacology Lysine Acetyltransferases CBP and p300 as Therapeutic Targets in Cognitive and Neurodegenerative Disorders
Current Pharmaceutical Design Regulation of Gene Expression by TDP-43 and FUS/TLS in Frontotemporal Lobar Degeneration
Current Alzheimer Research Nanoneuromedicines for Neurodegenerative Diseases
Nanoscience & Nanotechnology-Asia Stimuli-Responsive Nanocarriers for Drug Delivery to the Central Nervous System
Current Nanoscience Endocannabinoid System in Neurological Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Directions for Enhancement of the Therapeutic Efficacy of Mesenchymal Stem Cells in Different Neurodegenerative and Cardiovascular Diseases: Current Status and Future Perspectives
Current Stem Cell Research & Therapy RNAi Applications in Therapy Development for Neurodegenerative Disease
Current Pharmaceutical Design